← All trials
NCT00132626
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 1992
- Primary completion
- —
- Completion date
- Aug 31, 2005
- First posted
- Aug 22, 2005
- Last posted
- Apr 3, 2019
- Enrollment
- 500
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institute for Neurodegenerative DisordersLead sponsor
- Institute for Neurodegenerative DisordersOverall official - principal investigator
- Molecular NeuroImagingCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.